Tag: osé
OSE: entry into force of the license agreement with AbbVie – 04/17/2024 at 2:11 p.m.
(CercleFinance.com) – OSE Immunotherapeutics announced on Wednesday the entry into force of its global licensing agreement with AbbVie, aimed at developing a monoclonal antibody for the treatment of chronic inflammation.…
OSE Immunotherapeutics receives €8.4 million in public funding to support the Phase 3 clinical trial for the registration of the Tedopi® vaccine against lung cancer – 04/10/2024 at 6:00 p.m.
Nantes, France, April 10, 2024, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company has received non-dilutive financing of 8.4 million euros as part…
OSE Immunotherapeutics accentuates its losses in 2023
(AOF) – OSE Immunotherapeutics announces a cash position of 18.7 million euros as of December 31, 2023, to which will be added $48 million expected under the agreement with AbbVie…
OSE Immunotherapeutics announces the end of recruitment in the Phase 2 clinical study of Lusvertikimab evaluated in patients suffering from ulcerative colitis – 03/18/2024 at 07:30
Nantes, France – March 18, 2024, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the end of recruitment in the Phase 2b clinical trial evaluating the…
OSE Immuno: end of recruitment of a trial for UC
(CercleFinance.com) – OSE Immunotherapeutics today announces the end of recruitment in the Phase 2b clinical trial evaluating the IL-7 receptor antagonist monoclonal antibody Lusvertikimab (OSE-127) in patients with ulcerative colitis…
OSE Immuno: end of recruitment of a trial for RCH – 03/18/2024 at 08:01
(CercleFinance.com) – OSE Immunotherapeutics today announces the end of recruitment in the Phase 2b clinical trial evaluating the IL-7 receptor antagonist monoclonal antibody Lusvertikimab (OSE-127) in patients with ulcerative colitis…
Ose immuno: End of recruitment of a trial for UC
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
OSE Immunotherapeutics: partnership with AbbVie for OSE-230
By Arnaud Bivès Published on 02/28/2024 at 7:57 a.m. (Boursier.com) — OSE Immunotherapeutics and AbbVie announce a…
Unusual volumes on the stock market today: Ose Immunotherapeutics, Teleperformance
During this stock market session on Wednesday February 28, 2024, particularly high trading volumes were detected on the French market. Today, it is the Ose Immunotherapeutics stock that stands out,…
OSE Immuno: the title soars, partnership with AbbVie – 02/28/2024 at 11:45
(CercleFinance.com) – OSE Immunotherapeutics shares soared on the Paris Stock Exchange on Wednesday following the signing of a strategic partnership with the American biopharmaceutical group AbbVie. Around 11:30 a.m., the…
Ose Immunotherapeutics jumps after its partnership with Abbvie
(AOF) – Ose Immunotherapeutics (+54.61% to 5.11 euros) posts the strongest increase in the SRD market after announcing a global collaboration and licensing agreement with the American Abbvie to develop…
OSE Immunotherapeutics: new positive results against advanced solid tumors
(AOF) – OSE Immunotherapeutics presents the latest positive results from the Phase 1/2 clinical evaluation of its product OSE-279 in advanced solid tumors at the 2024 ESMO Targeted Anticancer Therapies…